Centogene, a Rostock, Germany-based leader in the field of genetic diagnostics for rare diseases, raised a €25m Series A financing.
The round was led by TVM Capital Life Science together with participation from DPE Deutsche Private Equity, Careventures and CIC Capital. In conjunction with the funding, Dr. Hubert Birner, TVM Capital Life Science, Eric Souetre, Careventures, and Guido Prehn, DPE Deutsche Private Equity, will join the Supervisory Board of Centogene.
The company intends to use the funds to expand its R&D activities, including biomarkers and companion diagnostic solutions, as well as broadening its global genetic diagnostics activities for early, precise diagnosis and treatment of rare diseases, and to increase its presence in the U.S. and China and to expand in other regions, mainly in the MENA region and Latin America.
Founded in 2005 and led by Prof. Arndt Rolfs, MD, CEO and Founder, Centogene provides test portfolios of over 3,100 single genes, including 200 panels, whole exome and whole genome testing. The company is currently receiving samples from over 110 countries, with approximately 120,000 analyzed individuals in their proprietary database – CentoMD®, a fully curated, mutation database for rare diseases.
Centogene had approximately 300 employees as of 31 May 2017.